Dementia Matters

Dr. Annalise Rahman-Filipiak joins the podcast to discuss her research focused on disclosing neuroimaging biomarkers across diverse populations. She addresses why some people might want to know their biomarker results, while others might not, and how careful disclosure of these results to at-risk individuals may help prepare them and their families for the future through personalized treatment, research engagement, advanced planning and emotional support. Guest: Annalise Rahman-Filipiak, PhD, assistant professor, neuropsychologist, department of psychiatry, University of Michigan Show Notes Learn more about Dr. Rahman-Filipiak on the University of Michigan’s website. Read Dr. Rahman-Filipiak’s article, “Interest in and perceived benefits and risks of Alzheimer’s disease clinical and biomarker results disclosure among diverse participants and care partners,” at the journal Alzheimer’s & Dementia website. Follow Dr. Rahman-Filipiak on Twitter @RahFlipPhD. Connect with us Find transcripts and more at our website. Email Dementia Matters: dementiamatters@medicine.wisc.edu Follow us on Facebook and Twitter. Subscribe to the Wisconsin Alzheimer’s Disease Research Center’s e-newsletter.

Dr. Elizabeth Bukowy discusses the importance of palliative care for individuals with dementia, emphasizing the need for early conversations on end-of-life care. She highlights the challenges in discussing prognosis and code status with patients and families and offers strategies to initiate these difficult conversations while ensuring quality of life is maintained.

When seeking medical information and treatment, different racial and ethnic groups may require specially tailored information to relate to, understand and apply to their own experiences. In this episode, Dr. Fayron Epps joins the podcast to talk about the unique experiences of African American caregivers and her lab's work to provide education and assistance to their needs. Epps seeks to promote quality of life for families affected by dementia through research, education and service. This episode is part of a special three-part series highlighting speakers from the Wisconsin Alzheimer’s Institute’s 20th Annual Update in Alzheimer’s Research and Related Dementias. Guest: Fayron Epps, PhD, RN, FGSA, FAAN, assistant professor, Nell Hodgson Woodruff School of Nursing, Emory University, principal investigator, Faith Village Research Lab, founder, Alter Show Notes Learn more about the 20th Annual Update in Alzheimer’s Disease and Related Dementias on the Wisconsin Alzheimer’s Institute’s website. Watch the full keynotes of the event on our YouTube channel. Dr. Epps’ keynote starts at 1:13:37 in the recording. Learn more about Dr. Epps on Alter’s website. Connect with us Find transcripts and more at our website. Email Dementia Matters: dementiamatters@medicine.wisc.edu Follow us on Facebook and Twitter. Subscribe to the Wisconsin Alzheimer’s Disease Research Center’s e-newsletter.

Mild cognitive impairment (MCI) is an emerging term in the field of Alzheimer’s disease and related dementias, characterized as the stage between the expected decline in memory and thinking that happens with age and the more severe decline of dementia. In this episode, Dr. Ronald Petersen joins the podcast to talk about how MCI compares to dementia, its many causes, and the impact of new lifestyle and drug interventions on its progression, as well as how his career led him to study Alzheimer's disease and MCI. This episode is part of a special three-part series highlighting speakers from the Wisconsin Alzheimer’s Institute’s 20th Annual Update in Alzheimer’s Disease and Related Dementias. Guest: Ronald C. Petersen, MD, PhD, director, Mayo Clinic Alzheimer's Disease Research Center, director, Mayo Clinic Study of Aging, Cora Kanow Professor of Alzheimer’s Disease Research, Mayo Clinic College of Medicine Show notes Learn more about the 20th Annual Update in Alzheimer’s Disease and Related Dementias on the Wisconsin Alzheimer’s Institute’s website. Watch the full keynotes of the event on our YouTube channel. Dr. Petersen’s keynote starts at 22:12 in the recording. Learn more about Dr. Petersen in his bio on his website. Connect with us Find transcripts and more at our website. Email Dementia Matters: dementiamatters@medicine.wisc.edu Follow us on Facebook and Twitter. Subscribe to the Wisconsin Alzheimer’s Disease Research Center’s e-newsletter.

In a special episode of Dementia Matters, Drs. Cynthia Carlsson and Sterling Johnson join the podcast to discuss what they know from lecanemab’s clinical trials following the U.S. Food and Drug Administration’s (FDA) accelerated approval, granted on January 6, 2023. Guests: Cynthia Carlsson, MD, MS, director, Wisconsin Alzheimer’s Institute, and Sterling Johnson, PhD, leader, Wisconsin Registry for Alzheimer’s Prevention (WRAP), associate director, Wisconsin Alzheimer’s Disease Research Center and Wisconsin Alzheimer’s Institute Show Notes This episode was uploaded as an exclusive video episode on the Wisconsin ADRC YouTube page on February 13, 2023. Watch the video interview with Drs. Carlsson and Johnson here. In a previous episode of Dementia Matters, Dr. Chin gave a brief overview of lecanemab’s clinical trials. Listen to it on Spotify, Apple Podcasts, our website, or wherever you listen. Read more about the AHEAD study and A4 study at their respective websites. Connect with us Find transcripts and more at our website. Email Dementia Matters: dementiamatters@medicine.wisc.edu Follow us on Facebook and Twitter. Subscribe to the Wisconsin Alzheimer’s Disease Research Center’s e-newsletter.

Former Governor of Wisconsin, Martin Schreiber, returns to Dementia Matters to discuss different methods for communicating with a loved one with Alzheimer’s disease, including therapeutic fibbing. Governor Schreiber has been a widely outspoken advocate for Alzheimer’s disease while caring for his late wife Elaine, who passed away from the disease in April of 2022. In this episode, he also talks about his book, My Two Elaines, where he opens up about his experience as a caregiver. Guest: Martin Schreiber, Former Governor of Wisconsin (1977-1979), Former Lt. Governor of Wisconsin (1971-1977) Show Notes Learn more about Martin Schreiber and his book, My Two Elaines, at his website, or follow him on Facebook. Listen to Governor Schreiber’s previous appearance on our website or wherever you get your podcasts.  Connect with us Find transcripts and more at our website. Email Dementia Matters Follow us on Facebook and Twitter. Subscribe to the Wisconsin Alzheimer’s Disease Research Center’s e-newsletter.

In October 2022, the Alzheimer's Association named Dr. Joanne Pike, the current president of the Association, as the next CEO, succeeding Harry Johns who has served as CEO since 2005. In this episode, Pike and Johns join the podcast to share their insights on how the Alzheimer's Association has grown over the past few decades and the future plans of the association, as well as the next steps in Alzheimer's treatment from both community and medication perspectives. Guests: Joanne Pike, DrPH, president and CEO, Alzheimer’s Association, Alzheimer’s Impact Movement, and Harry Johns, former CEO, Alzheimer's Association, former CEO and president, Alzheimer's Impact Movement (AIM), trustee and former chair, World Dementia Council Show Notes Learn more about CMS's updated coverage on monoclonal antibody treatment and the Alzheimer's Association’s response at their website. Learn more about Part the Cloud at their website. Learn more about the Alzheimer's Association at their website. Learn more about Dr. Pike in her bio on her website. Learn more about Mr. Johns in his bio on his website. Connect with us Find transcripts and more at our website. Email Dementia Matters: dementiamatters@medicine.wisc.edu Follow us on Facebook and Twitter. Subscribe to the Wisconsin Alzheimer’s Disease Research Center’s e-newsletter.

Host Nathaniel Chin, MD, gives an overview of the new Alzheimer’s treatment Leqembi (lecanemab), and highlights results from the second and third phases of its clinical trials. On January 6, 2023, the U.S. Food and Drug Administration (FDA) approved Leqembi (lecanemab-irmb) via the Accelerated Approval pathway for the treatment of Alzheimer’s disease. Show Notes In the coming weeks, host Nathaniel Chin will be joined by Cynthia Carlsson, MD, MS, and Sterling Johnson, PhD, to further discuss lecanemab and the clinical trials’ results. A link to that episode will be added here following its release. Read the FDA’s news release regarding lecanemab’s accelerated approval on their website. Connect with us Find transcripts and more at our website. Email Dementia Matters: dementiamatters@medicine.wisc.edu Follow us on Facebook and Twitter. Subscribe to the Wisconsin Alzheimer’s Disease Research Center’s e-newsletter.

Host Nathaniel Chin, MD, starts the new year by discussing modifiable risk factors for Alzheimer’s disease, commenting on building healthy lifestyle habits for the new year, and reflecting as Dementia Matters celebrates five years of production. Show Notes “Dementia prevention, intervention, and care: 2020 report of the Lancet Commission” is mentioned at the 4:16 mark. Read the full report on The Lancet’s website. Our past episode, “Alcohol and the Brain: One Drink a Day Associated with Brain Shrinkage,” is mentioned at the 5:05 mark. Listen on our website, Spotify, Apple Podcasts, or wherever you listen.  Our past episode, “Study Finds Air Pollution a Risk Factor For Alzheimer’s Disease,” is mentioned at the 5:07 mark. Listen on our website, Spotify, Apple Podcasts, or wherever you listen. Our past episode, “AARP Study Show Stigma Surrounding Dementia Among Healthcare Professionals And General Public,” is mentioned at the 5:28 mark. Listen on our website, Spotify, Apple Podcasts, or wherever you listen. As mentioned at the 7:40 mark, learn more about the books The Power of Habit by Charles Duhigg and Atomic Habits by James Clear, on the authors’ respective websites. Listen to our past episode, “Impacts of Exercise on Brain Health,” mentioned at the 9:37 mark. Learn about the book, Why Sleep Matters by Matthew Walker, mentioned at the 11:14 mark. Connect with us Find transcripts and more at our website. Email Dementia Matters: dementiamatters@medicine.wisc.edu Follow us on Facebook and Twitter. Subscribe to the Wisconsin Alzheimer’s Disease Research Center’s e-newsletter.

It’s generally known that mitochondria are the powerhouse of cells, but did you know they can play a significant role in aging processes? Through the field of bioenergetics, scientists are looking to study how changes in mitochondria affect us as we age and their connection to Alzheimer’s disease. Dr. Russell Swerdlow joins the podcast to discuss the field of bioenergetics and how mitochondria can impact Alzheimer’s disease and other aspects of aging. Guest: Russell Swerdlow, MD, director, Kansas Alzheimer’s Disease Research Center, director, Heartland Center for Mitochondrial Medicine, professor of neurology, University of Kansas Show Notes Learn more about Dr. Russell Swerdlow at his bio on the University of Kansas Medical Center’s website. Connect with us Find transcripts and more at our website. Email Dementia Matters: dementiamatters@medicine.wisc.edu Follow us on Facebook and Twitter. Subscribe to the Wisconsin Alzheimer’s Disease Research Center’s e-newsletter.